Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach

BACKGROUND: The currently recommended dose of rituximab for primary membranous nephropathy is as high as that for lymphoma. However, the clinical manifestations of membranous nephropathy vary widely. Therefore, achieving individualized treatment is a topic that needs to be explored. This study asses...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Song, Deng, Zhenling, Wang, Yue, Bao, Wenhan, Zhou, Sijia, Cui, Zhuan, Zheng, Danxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213597/
https://www.ncbi.nlm.nih.gov/pubmed/37237260
http://dx.doi.org/10.1186/s12882-023-03206-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213597/
https://www.ncbi.nlm.nih.gov/pubmed/37237260
http://dx.doi.org/10.1186/s12882-023-03206-1

Ejemplares similares